New York, USA & Tel Aviv, Israel — February 26, 2026
NeuraLight has announced the presentation of next-generation brain-function biomarker readouts at AD/PD 2026, introducing a breakthrough neuroprogression measurement platform designed to detect neuroprotection signals in drug trials. The biomarker, validated across multiple international clinical studies, has demonstrated performance superior to current gold-standard methods used to track Parkinson’s disease progression, marking a significant advancement in neurodegenerative clinical research.
Functional Biomarkers Improve Disease Tracking
Unlike traditional endpoints based on symptom scoring or slow biological markers, NeuraLight’s platform directly measures neural pathway performance and functional brain activity. This enables earlier and more sensitive detection of disease progression, providing reproducible insights into how neurological disorders evolve over time.
Enabling Measurable Neuroprotection in Trials
The technology introduces a high-sensitivity functional endpoint capable of identifying whether investigational therapies deliver true neuroprotection rather than symptomatic relief. This is particularly relevant for emerging CNS treatments, including GLP-1–based and disease-modifying therapies, where proving slowed neurodegeneration remains a major regulatory challenge.
Advertisement
Scaling Across Global Drug Development Programs
NeuraLight’s AI-driven biomarker platform is already deployed across multiple pharmaceutical trials spanning Parkinson’s disease, ALS, MS, PSP, MSA and Huntington’s disease. By enabling scalable, quantitative brain-function measurement, the technology supports faster efficacy assessment, improved trial design and more precise regulatory evidence generation.
Source: NeuraLight press release
